Danippon Sumitomo Deal With BioSeek Could Be Model For Other Japanese Pharmas – BIO-Asia
This article was originally published in PharmAsia News
Executive Summary
TOKYO - BioSeek's deal last week with Danippon Sumitomo Pharma could be a model for additional deals between the Burlington, Calif.-based platform company and Japanese pharmas looking to de-risk preclinical decisions, according to BioSeek VP-Technology & Alliances Ivan Plavec
You may also be interested in...
Japanese Pharmaceutical Industry Realignment Speeds Up In 2008: Interview With President Of Dainippon Sumitomo
In an interview with Yomiuri News, Dainippon Sumitomo President Kenjiro Miyatake noted 2008 drug prices are estimated to be over five percent lower
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).